TCT-14 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) After PCI in Brazil and Japan: SYNERGY Stent With Prasugrel Monotherapy (10 mg or 3.75 mg)
Yoshinobu Onuma(University Hospital Galway), Patrick W. Serruys(Erasmus MC), Yosuke Miyazaki(Yamaguchi University), Shinichiro Masuda(Iwate Medical University), Norihiro Kogame(Amsterdam UMC Location University of Amsterdam), Masato Nakamura(Toho University), Takashi Muramatsu(Tokyo Dental College), Kai Ninomiya(Ollscoil na Gaillimhe – University of Galway), Shigetaka Kageyama(Ollscoil na Gaillimhe – University of Galway), Ken Kozuma(Teikyo University Hospital), Kuniaki Takahashi(University of Amsterdam), Taku Asano(St. Luke's International Hospital), Yuki Ishibashi(Erasmus University Rotterdam), Yuki Katagiri(University of Amsterdam), Shimpei Nakatani(Erasmus MC), Yoshihiro Morino(Iwate Medical University), Kengo Tanabe(Mitsui Memorial Hospital), Nozomi Kotoku(St. Marianna University School of Medicine)
Cited by 0
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
|New England Journal of Medicine|2002|4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k